Biotechnology - Asia-Pacific, Oncology


Current filters:


Popular Filters

1 to 25 of 26 results

Seattle Genetics earns $6 million milestone under Adcetris accord with Takeda

Seattle Genetics earns $6 million milestone under Adcetris accord with Takeda


US biotech firm Seattle Genetics says it will receive milestone payments from Japan’s Takeda Pharmaceutical…

AdcetrisAsia-PacificBiotechnologyFinancialMarkets & MarketingOncologySeattle GeneticsSouth AmericaTakeda Pharmaceuticals

Walvax Biotech to take 64% stake in Genor BioPharma for around $49 million

Walvax Biotech to take 64% stake in Genor BioPharma for around $49 million


China’s Walvax Biotech has revealed it plans to acquire a controlling 64% equity stake in Shanghai’s…

Asia-PacificBiosimilarsBiotechnologyChinaMergers & AcquisitionsOncology

Drug approvals for Bayer in USA and Japan

Drug approvals for Bayer in USA and Japan


There were two pieces of good news for German Pharma and chemicals major Bayer on Friday (November 22),…

AmgenAsia-PacificBayerBiotechnologyEyleaNexavarNorth AmericaOncologyOnyx PharmaceuticalsOphthalmicsPharmaceuticalRegeneronRegulation

Merck Serono signs $232 million deal with Chinese company for BeiGene-290

Merck Serono signs $232 million deal with Chinese company for BeiGene-290


Merck Serono has signed a global licensing, co-development and commercialization agreement for BeiGene-290…

Asia-PacificBeiGeneBiotechnologyChinaLicensingMerck SeronoOncology

Immutep and Eddingpharm sign accord for ImmuFact IMP321 in China


French biopharma Immutep and Chinese drugmaker Eddingpharm have entered into an agreement for the development,…

Asia-PacificBiotechnologyLicensingMarkets & MarketingOncologyResearch

Bayer gets Japanese OK for GI stromal tumors drug


German drug major Bayer (BAYN: DE) has received approval from the Ministry of Health, Labor and Welfare…


Bristol-Myers partners with South Korean firm on biopharma production


US pharma major Bristol-Myers Squibb (NYSE: BMY) has entered into a 10-year agreement under which Samsung…

Asia-PacificBiotechnologyBristol-Myers SquibbOncologyPharmaceuticalProductionSamsung BioLogics

Soligenix collaborates with SciClone in China for SGX942 as oral mucositis therapy


US clinical-stage biopharma firm Soligenix (OTCQB: SNGX) has entered into a personalized medicine collaboration…

Asia-PacificBiotechnologyLicensingOncologyResearchSciClone PharmaSGX942Soligenix

Additional indications in Japan for Roche's Avastin and Astellas' Prograf


Swiss drug major Roche (ROG: SIX) says that the Japanese Ministry of Health, Labor and Welfare (MHLW)…

Asia-PacificAstellas PharmaAvastinBiotechnologyImmunologicalsOncologyPharmaceuticalPrografRegulationRoche

Amgen and Astellas link up on drugs for unmet medical needs in Japan


World leading independent biotech firm Amgen (Nasdaq: AMGN) has joined forces with Japanese drug major…

AmgenAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaBiotechnologyCardio-vascularOncologyPharmaceuticalResearch

CMC Biologics and RuiYi link on MAb; Deal for Cynviloq rights in EU


Denmark and USA-based contract manufacturers CMC Biologics has entered into an agreement with China's…

Asia-PacificBiotechnologyCMC BiologicsCynviloqEuropeIGDRASOLLicensingOncologyPharmaceuticalResearchRuiYiSamyang BiopharmaceuticalsSorrento Therapeutics

New Zealand considers listing of Neulastim and Actemra


New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list pegfilgrastim…


Celgene's Revlimid approved in China for MM; gets PDUFA date in USA for mantle cell lymphoma


Celgene Corp's (Nasdaq: CELG) European subsidiary revealed that Revlimid (lenalidomide) has been granted…

Asia-PacificBiotechnologyCelgeneNorth AmericaOncologyRegulationRevlimid

Kyowa Hakko set to file for pegfilgrastim approval in Japan following strong Ph III data


Mid-size Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) on Friday released positive top-line results…

Asia-PacificBiotechnologyKyowa Hakko KirinOncologypegfilgrastimPharmaceuticalRegulationResearch

Nexavar use in Chinese patients nearly doubled in 2012


Use of Nexavar (sorafenib, from Bayer [BAYN: DE] and Onyx Pharmaceuticals) has nearly doubled in first-line…

AlimtaAsia-PacificBayerBiotechnologyEli LillyMarkets & MarketingNexavarOncologyPharmaceutical

News briefs on Ipsen/Galderma and YM BioSciences nimotuzumab assets


French drugmaker Ipsen (Euronext: IPN) and Switzerland-headquartered Galderma have expanded their collaboration…

Asia-PacificBiotechnologyCIMABDysportGaldermaInnoKeys PTEIpsenLicensingnimotuzumabOncologyPharmaceuticalSouth AmericaYM Biosciences

Regulatory briefs: Celgene's pomalidomide; Lundbeck's vortioxetine


US biotech firm Celgene (Nasdaq: CELG) says that the US Food and Drug Administration's Oncologic Drugs…

Asia-PacificBiotechnologyCelgeneLundbeckNeurologicalNorth AmericaOncologyPharmaceuticalpomalidomideRegulationvortioxetine

PharmaEngine and Nanobiotix sign Asia-Pacific deal for NBTXR3


French nano-medicines group Nanobiotix has entered into a strategic partnership with PharmaEngine (TWO:…


Alnylam and Ascletis collaborate to develop ALN-VSP for liver cancers in China


US RNAi therapeutics specialties Alnylam Pharmaceuticals (Nasdaq: ALNY) and Ascletis Pharmaceuticals,…

ALN-VSPAlnylam PharmaceuticalsAscletis PharmaceuticalsAsia-PacificBiotechnologyLicensingOncology

China's Hisun gains access to Enzon technology


US biotech firm Enzon Pharmaceuticals (Nasdaq: ENZN) and Chinese drugmaker Zhejiang Hisun Pharmaceuticals…

Asia-PacificBiotechnologyEnzon PharmaceuticalsLicensingOncologyPEG-SN38PharmaceuticalZhejiang Hisun Pharma

Daiichi Sankyo debuts bone cancer drug Ranmark in Japan


Following National Health Insurance price listing yesterday, Japanese drug major Daiichi Sankyo (TYO:…

AmgenAsia-PacificAstraZenecaBiotechnologyDaiichi SankyodenosumabMarkets & MarketingOncologyPharmaceuticalRanmark

Apexigen licenses MAb to Gansu Duyiwei for China


Privately-held US biopharma firm Apexigen has entered into a collaboration to grant an exclusive license…

ApexigenAsia-PacificBiotechnologyGansu DuyiweiLicensingOncology

1 to 25 of 26 results

Back to top